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After resection, it is important to identify colon cancer patients, who are at a high risk of recurrence and who may benefit from
adjuvant treatment. The Petersen Index (PI), a prognostic model based on pathological criteria is validated in Dukes’ B and C disease.
Similarly, the modified Glasgow Prognostic Score (mGPS) based on biochemical criteria has also been validated. This study compares
both the scores in patients undergoing curative resection of colon cancer. A total of 244 patients underwent elective resection
between 1997 and 2005. The PI was constructed from pathological reports; the mGPS was measured pre-operatively. The median
follow-up was 67 months (minimum 36 months) during which 109 patients died; 68 of them from cancer. On multivariate analysis of
age, Dukes’ stage, PI and mGPS, age (hazard ratio, HR, 1.74, P¼0.001), Dukes’ stage (HR, 3.63, Po0.001), PI (HR, 2.05, P¼0.010)
and mGPS (HR, 2.34, Po0.001) were associated independently with cancer-specific survival. Three-year cancer-specific survival rates
for Dukes’ B patients with the low-risk PI were 98, 92 and 82% for the mGPS of 0, 1 and 2, respectively (Po0.05). The high-risk PI
population is small, in particular for Dukes’ B disease (9%). The mGPS further stratifies those patients classified as low risk by the PI.
Combining both the scoring systems could identify patients who have undergone curative surgery but are at high-risk of cancer-
related death, therefore guiding management and trial stratification.
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Colorectal cancer is the second most common cause of cancer
death in Western Europe and North America. Each year in the
United Kingdom, there are B35000 new cases and 16000 deaths
attributable to this disease. Colon cancer accounts for the majority
of disease with B22000 new cases and over 10000 deaths per year
(Cancerstats, 2004). Overall survival is poor; even in those patients
who undergo resection with curative intent, only half survive 5
years (McArdle and Hole, 2002).
Although Dukes’ stage is widely used to predict outcome in
colon cancer, it is also recognised that the survival of patients
within the staging categories is variable, particularly those with
Dukes’ B or T3/4 N0 tumours. There is a particular interest in
identifying subgroups of patients, with either Dukes’ stage B or
stage C disease with only one positive node, who may be at a
relatively high or low risk, respectively, of developing recurrent
cancer and therefore may or may not benefit from adjuvant
chemotherapy (Morris et al, 2007).
Consequently, considerable effort has been directed at refining
prognostic criteria. For example, numerous molecular-based
factors have been evaluated (Graziano and Cascinu, 2003).
Clinically useful factors should be routinely available, well
standardised and validated in a variety of different patient cohorts.
However, few molecular-based factors satisfy these criteria and
have been incorporated into routine clinical practice. There
remains a continuing need to identify clinically relevant factors
that would improve the prediction of survival in patients under-
going potentially curative surgery for colon cancer.
A score based on four routinely reported pathological criteria
(vascular invasion, peritoneal involvement, margin involvement
and tumour perforation) and the PI has been reported to predict
cancer-specific outcome in Dukes’ B colon cancer (Petersen et al,
2002). More recently, the PI has been validated as a prognostic
score in patients undergoing potentially curative resection for both
Dukes’ B and C cancer of the colon and the rectum (Morris et al,
2007). Similarly, an inflammation-based score, based on two
routinely measured acute phase proteins (C-reactive protein and
albumin) and the Glasgow Prognostic Score (GPS) has been
reported to predict the cancer-specific outcome in Dukes’ B colon
cancer (McMillan et al, 2007). The GPS has recently been validated
as a prognostic score in patients undergoing potentially curative
resection for both Dukes’ B and C cancer of the colon (Ishizuka
et al, 2007). To date, the relationship between the PI and GPS has
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snot been examined. Moreover, the application of both scores to a
single cohort of colon cancer patients has not earlier been
undertaken.
The aim of this study was to compare the prognostic value of the
tumour (PI) and inflammation-based (GPS) scoring systems in
patients undergoing resection for colon cancer.
MATERIALS AND METHODS
Patients with histologically proven colon cancer who, on the basis
of laparotomy findings and pre-operative abdominal computed
tomography, were considered to have undergone a potentially
curative resection between January 1997 and July 2005 in a single
surgical unit at the Royal Infirmary, Glasgow were included in this
study. These were consecutive, elective patients, who were entered
prospectively into a maintained database. The exclusion criteria
were: (i) emergency surgery, (ii) death within 30 days of surgery,
(iii) clinical evidence of infection or other inflammatory condi-
tions, such as inflammatory bowel disease or rheumatoid arthritis.
The tumours were staged using the conventional Dukes’ classifica-
tion (Dukes and Bussey, 1958).
The Petersen Index (PI) was constructed from the scores
allocated to the four selected pathological variables present in a
tumour specimen. Intra or extramural vascular invasion, perito-
neal involvement and margin involvement were allocated a score
of 1, and tumour perforation was allocated a score of 2. The
cumulative total is calculated and the PI considered low risk, in
which the score is between 0 and 1 and high risk with the score
between 2 and 5 (Petersen et al, 2002; Morris et al, 2007).
Blood samples were taken for routine laboratory measurements
of albumin and C-reactive protein measurement before surgery.
This is the standard practice in all cancer patients in our
institution. The coefficient of variation for these methods, over
the range of measurement, was o5% as established by routine
quality control procedures. The GPS was constructed as earlier
described (Forrest et al, 2003). Briefly, patients with both an
elevated C-reactive protein (410mgl
 1) and hypoalbuminaemia
(o35gl
 1) were allocated a score of 2. Patients in whom only one
of these biochemical abnormalities was present were allocated a
score of 1. Moreover, patients in whom neither of these
abnormalities was present were allocated a score of 0. Recently,
however, the GPS has been modified based on evidence that
hypoalbuminaemia, in patients with colorectal cancer without an
elevated C-reactive protein concentration, had no significant
association with cancer-specific survival. Therefore, patients with
an elevated C-reactive protein were assigned a modified GPS
(mGPS) of 1 or 2 depending on the absence or presence of
hypoalbuminaemia (McMillan et al, 2007).
The provision of adjuvant treatment was at the discretion of the
oncologist managing the patient after the multi-disciplinary team
assessment. Therefore, all biochemical and pathological results, as
well as patient co-morbidities were available to the oncologist for
making such decisions regarding adjuvant treatment.
This study was approved by the Research Ethics Committee,
Royal Infirmary, Glasgow.
Statistics
The grouping of variables was carried out using standard
thresholds. Univariate survival analysis was carried out using the
Kaplan–Meier method with the log-rank test. Multivariate survival
analysis and calculation of hazard ratios (HRs) were carried out
using Cox’s proportional-hazards model. A stepwise backward
procedure was used to derive a final model of the variables that
had a significant independent relationship with survival. To
remove a variable from the model, the corresponding P-value
had to be 40.05. Deaths up to 1 August 2008 were included in the
analysis. Analysis was carried out using the SPSS software (SPSS
Inc., Chicago, IL, USA).
RESULTS
Baseline clinico-pathological characteristics and the relationship
with a 5-year survival rate of the patients (n¼244), who
underwent curative surgery for colon cancer, are shown in Table 1.
The majority of patients were 65 years or older (73%), were male
(52%) and had Dukes’ stage A or stage B disease (59%). Fifty-six
(23%) patients received adjuvant chemotherapy. The median
number of lymph nodes sampled was 14 (range 3–52) for Dukes’ B
tumours and 14 (range 3–34) for Dukes’ C tumours. A majority of
the patients had no evidence of vascular invasion (67%), peritoneal
involvement (74%), resection margin involvement (91%) and
tumour perforation (97%), and had a low-risk PI (87%). Moreover,
a majority of the patients had C-reactive protein (51%) and
albumin (83%) concentrations in the normal range and a normal
mGPS (51%). Of the 40 patients with hypoalbuminaemia, 31 (78%)
had an elevated C-reactive protein concentration.
The minimum follow-up was 36 months; the median follow-up
of the survivors was 67 months. No patients were lost to follow-up.
During this period, 68 patients died of their cancer and a further 41
patients died of intercurrent disease. The univariate survival
analysis for baseline clinico-pathological characteristics is shown
in Table 1. On the univariate survival analysis of individual
variables, age (Po0.001), Dukes’ stage (Po0.001), vascular
invasion (Po0.001), peritoneal involvement (Po0.001), resection
margin involvement (Po0.001), tumour perforation (Po0.005),
C-reactive protein (Po0.001) and albumin (Po0.05) were
associated significantly with overall survival. Both the PI
(Po0.001) and the mGPS (Po0.001) were associated significantly
with overall survival (Table 1).
Furthermore, on the univariate survival analysis of individual
variables, age (Po0.001), Dukes’ stage (Po0.001), vascular
invasion (Po0.001), peritoneal involvement (Po0.001), resection
margin involvement (Po0.001), tumour perforation (Po0.005),
C-reactive protein (Po0.001) and albumin (Po0.005)
were associated significantly with cancer-specific survival.
On multivariate analysis of these significant variables, age
(HR, 1.80, 95% CI, 1.30–2.49, Po0.001), Dukes’ stage (HR, 3.14,
95% CI, 1.82–5.40, Po0.001), vascular invasion (HR, 2.18, 95% CI,
1.25–3.82, P¼0.006), C-reactive protein (HR, 2.09, 95% CI, 1.20–
3.65, P¼0.010) and albumin (HR, 2.33, 95% CI, 1.30–4.17,
P¼0.004) were associated independently with cancer-specific
survival. On the multivariate analysis of age, Dukes’ stage, PI
and mGPS, age (HR, 1.74, 95% CI, 1.27–2.39, P¼0.001), Dukes’
stage (HR, 3.63, 95% CI, 2.13–6.18, Po0.001), PI (HR, 2.05, 95%
CI, 1.19–3.56, P¼0.010) and mGPS (HR, 2.34, 95% CI, 1.65–3.31,
Po0.001) were associated independently with cancer-specific
survival.
The multivariate survival analysis in patients with Dukes’ stage
B and stage C disease is shown in Table 2. In those patients with
Dukes’ B stage disease, age (Po0.05), PI (Po0.001) and mGPS
(Po0.01) were associated independently with cancer-specific
survival. In those patients with Dukes’ C stage disease, age
(Po0.05) and mGPS (Po0.001) were associated independently
with cancer-specific survival.
The relationships between the PI and mGPS and cancer-specific
survival in Dukes’ B and C colon cancer are shown in Figures 1A
and B and Figures 2A and B, respectively. The 3-year
cancer-specific survival rate for patients with the low-risk
PI and Dukes’ B stage disease was 98, 92 and 82% for mGPS of
0, 1 and 2, respectively (Po0.05; Table 3). The 3-year cancer-
specific survival rate in all patients with Dukes’ C stage disease and
a low-risk PI was 84, 46 and 10% for a GPS of 0, 1 and 2,
respectively (Po0.001).
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sDISCUSSION
The PI was reported initially in Dukes’ B colon cancers (Petersen
et al, 2002). To date only one other study has validated the PI
as a prognostic score in Dukes’ B and C colon cancer, as well
as rectal cancer (Morris et al, 2007). The results of this study
further validate the PI in a different population of patients
undergoing potentially curative resection for colon cancer. Of the
244 colon cancer patients included in this study, only 17%
were classified as having a high-risk PI. The present PI
high-risk population among Dukes’ B cases was 9%; smaller
than the 29% of colon cancer cases originally reported by
Petersen (Petersen et al, 2002), but is more comparable with the
recent study by Morris et al (Morris et al, 2007), who also reported
9% of Dukes’ B colon cancers and rectal cancers as having a high-
risk PI.
Table 1 Clinico-pathological characteristics in patients undergoing potentially curative resection for colon cancer: univariate survival analysis
Patients
244 (%)
Overall 3-year
survival rate % (s.e.)
P-value
(log-rank)
Cancer 3-year
survival rate % (s.e.)
P-value
(log-rank)
Age
o65 years 65 (27) 95 (3) 95 (3)
65–74 years 72 (29) 76 (5) 84 (4)
475 years 107 (44) 61 (5) o0.001 68 (5) o0.001
Sex
Female 118 (48) 70 (4) 79 (4)
Male 126 (52) 79 (4) 0.416 81 (4) 0.832
Dukes’ stage
A 18 (7) 94 (5) 100 (0)
B 127 (52) 85 (3) 90 (3)
C 99 (41) 58 (5) 0.001 63 (5) o0.001
Adjuvant therapy
No 88 (77) 74 (3) 81 (3)
Yes 56 (23) 77 (6) 0.028 77 (6) 0.906
Date of surgery
1997–2001 116 (48) 77 (4) 81 (4)
2002–2005 128 (52) 73 (4) 0.514 79 (4) 0.773
Pathological characteristics
Vascular invasion
No 163 (67) 83 (3) 86 (3)
Yes 81 (33) 58 (5) o0.001 67 (5) o0.001
Peritoneal involvement
No 180 (74) 81 (3) 86 (3)
Yes 64 (26) 51 (6) 0.001 64 (6) o0.001
Margin involvement
No 221 (91) 76 (3) 82 (3)
Yes 23 (9) 57 (10) o0.001 60 (10) o0.001
Tumour perforation
No 308 (98) 75 (3) 81 (3)
Yes 6 (2) 50 (25) 0.001 50 (25) 0.002
Biochemical characteristics
C-reactive protein
p10mgl
 1 125 (51) 86 (4) 92 (3)
410mgl
 1 119 (49) 63 (4) o0.001 68 (4) o0.001
Albumin
X35gl
 1 204 (83) 78 (3) 83 (3)
o35gl
 1 40 (17) 58 (8) 0.001 67 (8) 0.004
Petersen Index
Low risk 203 (87) 79 (3) 84 (3)
High risk 41 (13) 54 (8) o0.001 61 (8) o0.001
mGPS
Low risk (0) 125 (51) 86 (3) 92 (3)
Intermediate (1) 88 (36) 68 (5) 72 (5)
High risk (2) 31 (13) 48 (9) o0.001 57 (9) o0.001
mGPS¼modified Glasgow Prognostic Score; s.e.¼standard error of mean.
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sThe basis of these differences in the classification of high-risk PI
between the studies is unclear. However, it may reflect differences
in case mix or variability in reporting those factors that form the
PI and discriminate between Dukes’ B and C cases. In the Petersen
study of Dukes’ B colon cancers, the prevalence of venous invasion
(extra and intramural) was 30%; in Morris’ paper on Dukes’ B and C
patients with both colon and rectal cancers, the prevalence of
extramural venous was14% and in this paper on colon cancers,
venous invasion was seen in 33% of colonic resections. In the three
studies, peritoneal involvement was seen in 42 (Petersen), 14
(Morris) and 26%, respectively (this study). The number of lymph
nodes can affect the Dukes’ staging and the mean number of lymph
nodes harvested was 21, 11 and 14 in the three studies. Finally, a
recent study from Australia reports a review of the slides by a
single expert pathologist of 82 patients reported to have Dukes’ B
cancer, but with no evidence of either venous invasion or serosal
involvement. Serosal involvement and/or venous invasion were
identified on review in 32% and these findings correlated with
survival (Stewart et al, 2007).
In spite of these drawbacks in pathology reports, both our study
and that of Morris and co-workers highlight the prognostic value of
the PI. In particular, given that the results of both the studies were
drawn from cases dissected and reported by a number of pathologists,
including trainee pathologists, they are likely to be representative of
‘real world’ pathology reporting used to inform multi-disciplinary
team meetings of high-risk patients with colon cancer. Therefore, we
would recommend the PI should be reported routinely in patients
having undergone resection for Dukes’ B colon cancer, for whom it
was designed, in which the HR for survival in our study was B10.
Our study shows for the first time that both tumour- (PI)
and inflammation-based (GPS) scoring systems have independent
prognostic value in patients undergoing potentially curative
resection for colon cancer. Although the PI measurement is
subject to variation in reporting, the pre-operative mGPS, based on
standard reliable laboratory measurements is objective and,
therefore, there is likely to be little variation in reporting.
It is of interest to consider how these results might be combined
in a clinical context. At present, patients with Dukes’ C tumours
Table 2 Clinico-pathological characteristics and 3-year cancer specific survival in patients undergoing potentially curative resection for Dukes’ B and
Dukes’ C colon cancer: multivariate survival analysis
Dukes’ B n¼127 (%) Three-year survival % (s.e.) Hazard ratio (95% CI) P-value
Age
o65 years 37 (29) 100 (0)
65–74 years 40 (31) 92 (4) 0.034
475 years 50 (40) 81 (6) 1.87 (1.05–3.34)
Sex
Female 61 (48) 90 (4)
Male 66 (62) 91 (4) 0.99 (0.39–2.51) 0.984
Adjuvant therapy
No 111 (87) 92 (3)
Yes 16 (13) 81 (10) 0.98 (0.22–4.44) 0.979
Petersen Index
Low 115 (91) 94 (2)
High risk 12 (9) 58 (14) 9.61 (3.27–28.26) o0.001
mGPS
Low 0 62 (49) 97 (2)
Intermediate 1 47 (37) 87 (5)
High risk 2 18 (14) 78 (10) 2.15 (1.19–3.87) 0.010
Dukes’ C n¼99 (%) Three-year survival % (s.e.) Hazard ratio (95% CI) P-value
Age
o65 years 25 (25) 88 (6)
65–74 years 25 (25) 66 (10)
475 years 49 (50) 48 (7) 1.72 (1.08–2.75) 0.022
Sex
Female 49 (49) 62 (7)
Male 50 (51) 64 (7) 1.25 (0.68–2.31) 0.477
Adjuvant therapy
No 59 (60) 54 (7)
Yes 40 (40) 75 (7) 0.92 (0.42–2.00) 0.832
Petersen Index
Low 70 (71) 63 (6)
High risk 29 (29) 63 (9) 1.16 (0.60–2.24) 0.655
mGPS
Low 0 50 (51) 83 (6)
Intermediate 1 37 (32) 51 (8)
High risk 2 12 (17) 24 (13) 2.80 (1.80–4.44) o0.001
CI¼confidence interval; mGPS¼modified Glasgow Prognostic Score; s.e.¼standard error of mean.
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sare offered adjuvant chemotherapy, whereas those patients with
Dukes’ A tumours are not. All the relevant studies concur that the
PI identifies Dukes’ B patients who are at high risk, and arguably
these patients should also be offered chemotherapy. Morris has
shown that patients with single node positive Dukes’ C tumours
had a better prognosis than patients with Dukes’ B tumours with a
PI 1. In this study, among patients with Dukes’ B tumours and a
low-risk PI, a high-risk mGPS indicated a statistically significant
poorer prognosis when compared with patients with pathologically
similar tumours who had a low-risk mGPS (Table 3). Such high-
risk patients may therefore be thought to benefit from adjuvant
chemotherapy.
The utility of the PI in predicting the response to chemotherapy
is not, to our knowledge, known. In contrast, there is evidence that
an elevated C-reactive protein of the mGPS not only identifies
those patients who are at an increased risk of recurrent disease, but
also those patients who are likely to benefit from adjuvant
chemotherapy (Crozier et al, 2006). Therefore, on the basis of the
available evidence, the mGPS should be included, together with the
PI, in the post-operative, multi-disciplinary assessment of patients
with primary operable colon cancer and the stratification of
patients entering randomised trials of adjuvant chemotherapy.
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Figure 1 (A) The relationship between low- and high-risk Petersen
Index (from top to bottom) and cancer-specific survival in Dukes’ B colon
cancer patients (Po0.001). (B) The relationship between increasing
modified Glasgow Prognostic Score (mGPS) (from the top to bottom) and
cancer-specific survival in Dukes’ B colon cancer patients (Po0.05).
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Figure 2 (A) The relationship between low- and high-risk Petersen
Index (from top to bottom) and cancer-specific survival in Dukes’ C colon
cancer patients (P¼0.195). (B) The relationship between increasing
modified Glasgow Prognostic Score (mGPS) (from the top to bottom) and
cancer-specific survival in Dukes’ C colon cancer patients (Po0.001).
Table 3 The relationship between the low-risk Petersen Index, and the
mGPS with a 3-year survival (%) in patients undergoing potentially curative
resection for Dukes’ B, single node positive Dukes’ C and Dukes’ C colon
cancer
Petersen Index Petersen Index
Dukes’ B Low risk (n¼115) High risk (n¼12)
mGPS
Low risk (0) 98% (n¼56) 82% (n¼6)
Intermediate (1) 92% (n¼42) 40% (n¼5)*
High risk (2) 82% (n¼17)** 0% (n¼1)**
mGPS(0–2) 94% (n¼115) 58% (n¼12)
Petersen Index Petersen Index
Dukes’ C Low risk (n¼70) High risk (n¼29)
mGPS
Low risk (0) 84% (n¼39) 76% (n¼11)
Intermediate (1) 46% (n¼24)*** 62% (n¼13)
High risk (2) 10% (n¼7)**** 40% (n¼5)***
mGPS(0–2) 63% (n¼70) 63% (n¼29)
mGPS¼modified Glasgow Prognostic Score. *Po0.1, **Po0.05, ***Po0.01,
****Po0.001: Association between the increasing mGPS and cancer-specific survival
on univariate analysis.
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mGPS before surgery and poor long-term cancer-specific survival
in patients with primary operable colon cancer is not clear.
A plausible explanation is that an elevated mGPS may reflect
compromised cell-mediated immunity, as an elevated C-reactive
protein and hypoalbuminaemia are associated with lymphocyto-
penia (Nozoe et al, 2000) and with an impaired T-lymphocytic
response in the tumour (Canna et al, 2005). Furthermore, the
presence of an elevated C-reactive protein concentration and
hypoalbuminaemia have also been shown to be associated with the
upregulation of components of innate immune system, including
complement and macrophage functions (Coussens and Werb,
2002; Du Klos and Mold, 2004). In addition, it is known that as part
of the systemic inflammatory response, there is a release of pro-
inflammatory cytokines and growth factors which may promote
tumour growth (Abramovitch et al, 1999; Canna et al, 2007).
Therefore, the mGPS may reflect host responses that impact
prognosis in colon cancer, whereas the PI might be considered to
provide prognostic information on tumour behaviour.
In summary, the results of this study validate the use of the PI in
predicting cancer-specific survival in patients undergoing elective
potentially curative for Dukes’ B colon cancer. Furthermore, the
results indicate that the mGPS further stratifies those patients with
Dukes’ B and single node positive Dukes’ C cancers, classified as
low risk by the PI. The PI and mGPS scoring systems could,
therefore, be combined at a multi-disciplinary meeting to identify
those patients with colorectal cancer who have undergone
potentially curative surgery but are at high risk of cancer related
death.
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